About 4DMT
4D Molecular Therapeutics (4DMT) is a pioneering clinical-stage biopharmaceutical company that is dedicated to unlocking the full potential of genetic medicine. Founded in 2013, 4DMT is focused on inventing and developing innovative gene therapy products specifically designed to address serious unmet medical conditions. Utilizing its proprietary 4DMT genetic medicine engine, the company aims to create transformative therapies that have the capacity to significantly improve patient lives and, in some cases, potentially cure diseases.
The company’s approach is built around its unique vector discovery platform, known as Therapeutic Vector Evolution, which leverages directed evolution technology—recognized with a Nobel Prize—to generate customized adeno-associated virus (AAV) vectors. This robust platform enables 4DMT to produce tailored and improved therapeutic profiles for gene delivery. With a strong pipeline of product candidates undergoing clinical trials, including treatments for conditions like wet age-related macular degeneration and Diabetic Macular Edema, 4DMT is making significant strides in advancing the field of genetic medicines. Through relentless innovation and a commitment to delivering results, 4D Molecular Therapeutics is not just creating therapeutic products; it is redefining what is possible in the realm of genetic medicine.